C hronic kidney disease (CKD), defined as presence of kidney dysfunction or damage, is a major public health problem because of its prevalence of 10% to 15% in many parts of the world and its contribution to adverse outcomes.
C hronic kidney disease (CKD), defined as presence of kidney dysfunction or damage, is a major public health problem because of its prevalence of 10% to 15% in many parts of the world and its contribution to adverse outcomes. 1, 2 The prevention of cardiovascular disease (CVD) is crucial, particularly in individuals with CKD, as they are more likely to die of CVD than to reach dialysis or die of kidney failure. 2 A recent report suggests that CKD is a health condition equivalent to coronary heart disease (CHD) in terms of high mortality risk. 3 Nevertheless, individuals with CKD show substantial variation in CVD risk. 1, 2 However, neither conventional CVD risk factors 4 nor conventional CKD measures capture the CVD risk gradient effectively, 5, 6 resulting in controversies as to how to classify CVD risk in people with CKD. 7, 8 Several studies demonstrate that nontraditional biomarkers of cardiac and kidney dysfunction or damage can improve risk classification in this population. 9, 10 However, it is unclear whether cardiac or kidney markers contribute more to improvement in CVD prediction in people with CKD. Thus, we compared several nontraditional cardiac and kidney markers on their improvement in CVD risk prediction among individuals with and without CKD. stages 1 and 2 were likely to be current smokers, but there were fewer current smokers in CKD stages 3 to 5. The proportion of blacks was higher in CKD stages 1 and 2 compared with non-CKD or CKD stages 3 to 5. The median value for every cardiac and kidney marker was higher in those with CKD compared with those without.
During a median follow-up of 11.9 years, there were 1672 CVD events (336 events in CKD; 872 CHD cases, 310 stroke cases, and 526 heart failure (HF) cases with 36 concurrent cases of 2 subtypes [mostly CHD and HF]). Cumulative incidences of composite CVD and each individual CVD outcome are shown in Figure I in the online-only Data Supplement. The overall incidence rate of CVD was 18.1 per 1000 person-years (38.0 per 1000 person-years in CKD and 16.0 per 1000 person-years in non-CKD). Those with CKD had higher incidence rate of CVD than those without, as shown by the red line located above the blue line at any given level of nontraditional markers (Figure) . Although there was generally a graded positive association between each marker and CVD risk, the risk gradient tended to be steeper for cardiac CKD stages 3-5 and 1-2 were defined as eGFRcre <60 mL/min/1.73 m 2 and ACR ≥30 mg/g+eGFRcre ≥60, respectively. All variables differed across the groups with a P-value <0.0001 except for % female (P=0.635) and HDL cholesterol (P=0.0007). Values are mean (SD), %, or median (IQR). ACR indicates urinary albumin-to-creatinine ratio; B2M, β 2 microglobulin; BTP, β-trace protein; CKD, chronic kidney disease; cTnT, cardiac troponin T; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; and NT-proBNP, N-terminal pro-B-type natriuretic peptide. markers than for kidney or inflammatory markers, regardless of CKD status.
When we further adjusted for other conventional factors, hazard ratios (HRs) of CVD per 1 SD increment were larger for cardiac markers than for kidney markers, particularly in CKD population ( Table 2 ). The results were much the same when we specifically adjusted for renin-angiotensin inhibitors and β-blockers or further adjusted for the use of statin (data not shown). Further adjustment for the interaction of these nontraditional markers with CKD status on CVD risk was significant for cardiac troponin T (cTnT; P=0.019) and β 2 microglobulin (B2M; P=0.008). Among CVD types, the HRs for both cardiac markers were highest for HF followed by CHD. Similar results were observed when CHD cases only based on Figure. Adjusted incidence rate of cardiovascular disease (CVD) in those with and without chronic kidney disease (CKD) according to novel cardiac and kidney markers and their distributions. Adjusted incidence rate of CVD in those with and without CKD according to cardiac and kidney markers and their distributions. The solid lines (red for CKD and blue for non-CKD) show estimated incidence rates of CVD (per 1000 person-years) and 95% confidence intervals (whiskers and shaded area) with spline (knots at thresholds defining quartiles) for (A) cardiac troponin T (cTnT), (B) N-terminal pro-B-type natriuretic peptide (NT-proBNP), (C) cystatin C, (D) β 2 microglobulin (B2M), (E) β-trace protein (BTP), and (F) high-sensitivity C-reactive protein (hsCRP). The incidence rate was adjusted to mean age, men, and whites, and the plot was truncated at 0.5th and 99.5th percentile of each marker. The dash lines (red for CKD and blue for non-CKD) show the kernel density estimate for the distribution of each marker.
coronary revascularization, and hard CHD cases of myocardial infarction and fatal CHD were analyzed separately (data not shown). The associations of cystatin C and B2M with CVD outcomes were similar to or slightly stronger than that of high-sensitivity C-reactive protein (hsCRP) in people with CKD. B2M demonstrated similar HRs of CVD outcomes as the cardiac markers in those without CKD. The HRs for cTnT and N-terminal pro-B-type natriuretic peptide (NT-proBNP) remained significant for composite CVD even when they were simultaneously included in the model along with conventional factors (data not shown). The higher HRs of CVD for cardiac markers compared with kidney markers in CKD were similarly observed, when every marker was modeled by its quartiles (Table I in the online-only Data Supplement).
In the CKD group, c-statistics for composite CVD significantly improved, from a base of 0.679 with only conventional predictors, for 0.036 (95% confidence interval, 0.016-0.056) with added NT-proBNP, 0.032 (0.009-0.054) with cTnT, and 0.015 (0.001-0.026) with B2M (Table 3) . In this group, the categorical net reclassification improvement for CVD was significant for both cardiac markers (0. Table 4 ). hsCRP did not contribute to significant difference in c-statistic or categorical net reclassification improvement for CVD in CKD (Tables 3 and 4 ). The contribution of both cardiac markers to better CVD risk discrimination was largely consistent between CKD stages 1 and 2 and 3 to 5, whereas that of kidney markers was more evident in stages 3 to 5 than in stages 1 and 2 (Table II in the online-only Data Supplement) although confidence intervals were wide because of small sample size in each stage. The prediction improvement by cTnT and NT-proBNP was consistent even when estimated glomerular filtration rate based on serum creatinine (eGFRcre) was added in the base model (Tables III and IV in the online-only Data Supplement) and was further enhanced when these cardiac markers were taken into account together (Tables 3 and 4) . Consistent, but more evident, improvement was observed for continuous net reclassification improvement and integrated discrimination improvement (Tables V and VI in the online-only Data Supplement). When we directly compared cTnT or NT-proBNP with every kidney marker for CVD prediction, there was ≥1 statistic demonstrating significantly better prediction by cardiac markers in CKD ( Table 5 ).
The superiority of cardiac markers to kidney markers for CVD prediction was largely consistent in those without CKD although the prediction statistics for cardiac markers were more prominent in CKD than in non-CKD (Tables 3 and 4 ). In non-CKD, the prediction improvement for B2M was greater than that for the other 2 kidney markers and similar to that for the 2 cardiac markers.
When we analyzed CHD, stroke, and HF separately, although there were some variations, the best value for each statistic was generally observed for a model with either cTnT or NT-proBNP, regardless of CKD status (Tables 3  and 4 ). In both CKD and non-CKD, the improvement in prediction by these cardiac and kidney markers was most evident for HF.
Overall, conventional kidney measures of eGFR and urinary albumin-to-creatinine ratio did not outperform cTnT and NT-proBNP for predicting CVD outcomes in both CKD and non-CKD groups (Tables VII and VIII in the online-only Data Supplement). Finally, we repeated the analyses using eGFR based on serum creatinine and cystatin C 11 for defining CKD population and observed similar results (data not shown).
Discussion
This study compared the additional value of several cardiac and kidney markers for CVD risk prediction among individuals with and without CKD. In line with previous reports not necessarily specific to CKD populations, 9,12-16 every marker was associated with incident CVD, independent of conventional risk factors, and contributed to improvement in CVD prediction in both CKD and non-CKD. Of note, the associations of cTnT and NT-proBNP with CVD were stronger than those of 3 nontraditional kidney markers, cystatin C, B2M, and β-trace protein or, well-studied nontraditional marker, hsCRP. Hence, the improvement in CVD prediction was most evident for these cardiac markers, particularly in people with CKD. 84 ) higher cTnT. B2M indicates β 2 microglobulin; BTP, β-trace protein; CI, confidence interval; cTnT, cardiac troponin T; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
There has been concern about cTnT and NT-proBNP as predictors of CVD in CKD populations because their levels can increase as a consequence of kidney dysfunction (ie, volume overload and reduced kidney excretion) and may not necessarily reflect cardiac abnormalities. 10 However, several recent studies report the associations between these cardiac markers and poor prognosis, even among this specific population. 10, 17, 18 Of importance, the associations of cTnT and NT-proBNP with CVD were independent of kidney function and actually stronger in those with CKD than in those without in our study. This study expands current knowledge in several other aspects. First, the rigorous assessment of risk prediction statistics is clinically important because a significant association does not necessarily ensure improvement in risk prediction. 19 The prediction improvement for CVD by cTnT and NT-proBNP in our study was considerably larger than what was recently reported for the combination of total cholesterol, highdensity lipoprotein cholesterol, and hsCRP for CHD prediction in a meta-analysis. 20 Second, cTnT and NT-proBNP improved risk prediction independently of each other, and their combination may gain more than each separately, probably because they reflect different pathological conditions of the heart. 16, 21 Third, their contributions to improved CVD prediction were largest for HF, followed by CHD and stroke. Fourth, we confirmed prediction values of these cardiac markers in people without history of CVD (ie, the primary prevention setting). 10, 22 Finally, these cardiac markers outperformed nontraditional kidney markers including cystatin C for CVD prediction. This is a clinically important aspect when we consider parsimonious prediction models given the cost to measure nontraditional predictors.
It may not be surprising that both cTnT and NT-proBNP performed better than kidney markers for CVD prediction because these cardiac markers reflect subclinical alteration of cardiac structure or function, which would progress to clinical HF or CHD. Nevertheless, our results may have important clinical implications because identifying high-risk individuals is an important element for prevention strategy. Future studies are warranted to assess whether cTnT and NT-proBNP would help guide prevention strategies, eg, statin therapy, 22 in people with CKD. Also, given that individuals with CKD are prone to vascular calcification, [23] [24] [25] [26] comparison of cardiac markers with markers of calcification such as coronary artery calcium and serum calcium or phosphate would be important.
Our observations for kidney markers might be conservative because, by stratifying our study population according to CKD status, we restricted the variance of kidney markers, in each of CKD and non-CKD. Nevertheless, these kidney measures contributed to better CVD prediction more evidently in CKD stages 3 to 5 than in stage 1 and 2. Also, cystatin C and B2M performed better than hsCRP for CVD prediction in the entire CKD population. Also, our analytic frame is in line with a recognized approach to use novel kidney filtration markers in addition to eGFRcre and urinary albumin-to-creatinine ratio to identify the high-risk CKD population (eg, a triple-marker approach using serum creatinine, cystatin C, and urinary albumin-to-creatinine ratio). BTP, β-trace protein; CHD, coronary heart disease; CKD, chronic kidney disease; cTnT, cardiac troponin T; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; and NT-proBNP, N-terminal pro-B-type natriuretic peptide. *CKD was defined as eGFRcre <60 mL/min/1.73m 2 or urinary albumin-to-creatinine ratio
27,28
Although additional kidney filtration markers may be useful to more precisely estimate kidney function or predict kidney outcomes, 9 our results suggest that overall cardiac-specific markers would be more useful to predict CVD outcomes in CKD population.
Among kidney markers, B2M predicted CVD similarly to cystatin C in CKD and was the best in non-CKD. B2M is a polypeptide, forming a small subunit of the major histocompatibility class-I molecule on the surface of nucleated human cells and thrombocytes and is eliminated by the kidney. 9, 29 A few studies have reported a significant prospective association between B2M and CVD, 29, 30 but the mechanisms by which B2M confers CVD risk is not well understood. B2M may merely be a good marker for kidney dysfunction, 31 but some investigators have suggested nonkidney pathways. B2M is known as a marker of inflammation 31 and may also directly damage vessels through its involvement in amyloid formation. 29 Nevertheless, B2M warrants further investigations in the context of CVD.
There are several limitations in our study. Few participants had CKD. However, it is still one of the largest CKD data sets ever tested for both cTnT and NT-proBNP, as well as nontraditional kidney and inflammatory markers, in terms of CVD prediction. 10 Moreover, most participants with CKD were at stages 1 to 3. However, the vast majority of people with CKD are at these stages. 32 Also, we did not have information on causes of CKD. However, because this is a community-based cohort, it is highly likely that 2 most prevalent causes of CKD, hypertension and diabetes mellitus, 33 play a major role in most cases, and Table 1 is consistent with this perspective. The mean age of our study population at baseline was 62 years and thus a majority of women in our study were likely to be postmenopausal. Thus, our results may not be generalizable to premenopausal women. The frequency of statin prescription has substantially increased since the baseline of this study (1996) (1997) (1998) , 34 and its impact on our estimates is unclear. We had only a single measurement of cardiac and kidney markers and thus there might be a degree of misclassification because of their short-term variability, leading to attenuated/conservative estimates. Identification of HF cases predominantly relied on International Classification of Diseases codes in hospital records and thus might not capture mild cases managed in outpatient setting.
In conclusion, cardiac and kidney dysfunction/damage markers improved CVD prediction in those with and without CKD. The improvement was more evident for cTnT and NT-proBNP compared with kidney markers, particularly in CKD. Our results suggest that these cardiac markers are useful to better classify CVD risk in CKD population. microglobulin; BTP, β-trace protein; CHD, coronary heart disease; CKD, chronic kidney disease; cTnT, cardiac troponin T; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; NA, NRI was not available because of no reclassification to higher or lower risk categories in some bootstrap samples; NRI, net reclassification improvement; and NT-proBNP, N-terminal pro-B-type natriuretic peptide. *CKD was defined as eGFRcre <60 mL/min/1.73m 2 or urinary albumin-to-creatinine ratio ≥30 mg/g. Positive values indicate better prediction with a model with cardiac marker. B2M indicates β 2 microglobulin; BTP, β-trace protein; CKD, chronic kidney disease; cTnT, cardiac troponin T; IDI, integrated discrimination improvement; NRI, net reclassification improvement; and NTproBNP, N-terminal pro-B-type natriuretic peptide.
*CKD was defined as eGFRcre <60 mL/min/1.73m 2 or urinary albumin-to-creatinine ratio ≥30 mg/g.
